<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="100020"><DrugName>HDDO-1604</DrugName><DrugSynonyms><Name><Value>HOB-075</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HDDO-1604</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="90" type="ciIndication"><TargetEntity id="10012267" type="MEDDRA"></TargetEntity><TargetEntity id="D003704" type="MeSH"></TargetEntity><TargetEntity id="-1720562635" type="omicsDisease"></TargetEntity><TargetEntity id="100" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3" type="Action"><TargetEntity id="235" type="Mechanism">5-HT Reuptake Inhibitors</TargetEntity></SourceEntity><SourceEntity id="18" type="Action"><TargetEntity id="381" type="Mechanism">Angiotensin-I Converting Enzyme (ACE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00039" type="ciTarget"><TargetEntity id="55189613116363" type="siTarget">Angiotensin-converting enzyme</TargetEntity><TargetEntity id="2465" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="90">Dementia</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="18">ACE inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="3">5-HT uptake inhibitor</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C9A</Code><Name>ACE INHIBITORS, PLAIN</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N6A4</Code><Name>SSRI antidepressants</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-05T17:15:59.000Z</LastModificationDate><ChangeDateLast>2017-07-24T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HDDO-1604 (previously HOB-075), a combination of an angiotensin converting enzyme (ACE) inhibitor and a selective serotonin re-uptake inhibitor (SSRI), for the potential treatment of dementia including Alzheimer's  affecting elderly people [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;], [&lt;ulink linkID="1946873" linkType="Reference"&gt;1946873&lt;/ulink&gt;]. In November 2015, the program was in preclinical development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]; by February 2017, toxicity and PK studies had been completed  [&lt;ulink linkID="1905186" linkType="Reference"&gt;1905186&lt;/ulink&gt;]. However, in November 2018, the program was no longer listed as one being in development [&lt;ulink linkID="2029123" linkType="Reference"&gt;2029123&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The program was previously being evaluated for depression  [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. However, by February 2017, the focus had become dementia including Alzheimer's [&lt;ulink linkID="1905186" linkType="Reference"&gt;1905186&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00039"><Name>ACE</Name><SwissprotNumbers><Swissprot>P09470</Swissprot><Swissprot>P12820</Swissprot><Swissprot>P12821</Swissprot><Swissprot>P12822</Swissprot><Swissprot>P47820</Swissprot><Swissprot>Q10714</Swissprot><Swissprot>Q10715</Swissprot><Swissprot>Q10751</Swissprot><Swissprot>Q50JE5</Swissprot><Swissprot>Q6Q4G4</Swissprot><Swissprot>Q9GLN7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>